E74.02 Pompe disease

Name of the Condition

• Pompe disease (ICD-10 Code E74.02)

Summary

Pompe disease is a rare inherited metabolic disorder caused by a deficiency of the enzyme acid alpha-glucosidase (GAA). This deficiency leads to the abnormal accumulation of glycogen in lysosomes, primarily affecting skeletal and cardiac muscle tissues. The condition disrupts cellular energy metabolism and can result in progressive muscle weakness and organ dysfunction.

Causes

Pompe disease is caused by genetic mutations in the GAA gene, which encodes the acid alpha-glucosidase enzyme. These mutations are inherited in an autosomal recessive pattern, meaning both parents must carry a mutated gene for a child to be affected. The enzyme deficiency impairs glycogen breakdown, leading to toxic buildup in muscle cells.

Risk Factors

• Genetic predisposition or family history of Pompe disease.
• Consanguinity (closely related parents), increasing the likelihood of inheriting recessive mutations.
• Ethnic or population-specific prevalence for certain GAA gene variants.

Symptoms

Symptoms vary by age of onset and may include:

• Progressive muscle weakness, particularly in the limbs and respiratory muscles.
• Cardiomyopathy (enlarged heart) in infantile-onset cases.
• Respiratory insufficiency or failure.
• Delayed motor milestones in infants.
• Fatigue and exercise intolerance.

Diagnosis

Diagnosis involves clinical evaluation, family history, and laboratory tests. Blood tests may show elevated creatine kinase (CK) levels. Confirmatory testing includes measuring GAA enzyme activity in blood or tissue samples, or genetic testing for GAA gene mutations. Muscle biopsy may reveal glycogen accumulation.

Treatment Options

Treatment focuses on managing symptoms and slowing disease progression. Enzyme replacement therapy (ERT) with alglucosidase alfa is available for some patients. Supportive care includes respiratory support, physical therapy, and cardiac monitoring. Clinical trials may offer additional therapeutic options.

Prognosis and Follow-Up

Prognosis depends on the age of onset and severity. Infantile-onset cases often have a more rapid progression, while late-onset forms may progress more slowly. Regular follow-up with a multidisciplinary team (neurologist, cardiologist, pulmonologist) is essential to monitor organ function and adjust treatment.

Complications

• Respiratory failure due to muscle weakness.
• Cardiac complications, including heart failure.
• Mobility limitations and dependence on assistive devices.
• Increased susceptibility to infections.

Lifestyle & Prevention

While Pompe disease cannot be prevented, supportive lifestyle measures may improve quality of life. These include:

• Regular physical therapy to maintain muscle strength.
• Respiratory exercises or devices to support breathing.
• Nutritional planning to address feeding difficulties.
• Genetic counseling for families with a history of the condition.

When to Seek Professional Help

Seek medical attention if you or your child experiences unexplained muscle weakness, respiratory distress, or delayed motor development. Early diagnosis and intervention can improve outcomes. Prompt care is especially critical for infants with suspected cardiomyopathy.

Tips for Medical Coders

When coding for Pompe disease (E74.02), ensure documentation supports the diagnosis, including clinical findings, enzyme testing, or genetic results. Differentiate between infantile and late-onset forms if specified, as this may impact coding specificity. Verify that the code aligns with the patient’s age, symptoms, and diagnostic confirmation.